Host: The Japanese Pharmacological Society
Name : The 97th Annual Meeting of the Japanese Pharmacological Society
Number : 97
Location : [in Japanese]
Date : December 14, 2023 - December 16, 2023
Shionogi's strategic plan, STS2030, represents a pivotal shift from a conventional research-focused pharmaceutical entity to a provider of "Healthcare as a Service (HaaS)," primarily focused on addressing customer healthcare needs.
We are pursuing several key initiatives. These include investments in digital health solutions, such as mobile apps, wearable devices, and data analytics platforms for real-time patient health monitoring. They are also fostering collaborations with digital health startups and technology companies to fuse pharmaceutical expertise with advanced tech for innovative healthcare solutions.
Furthermore, a strong commitment to patient-centricity is evident, with efforts to enhance patient engagement via digital channels, providing easy access to information and virtual care platforms for remote consultations and monitoring.
In summary, Shionogi's strategy centers on harnessing digital advancements in the pharmaceutical sector. The STS2030 plan signifies our transformation into a HaaS provider, emphasizing digital health, collaborations, process enhancement, and patient-centric approaches. Our goal is to remain at the forefront of innovation in an ever-evolving healthcare landscape.
